Helen Sabzevari
President & Chief Executive Officer Precigen
Dr. Helen Sabzevari is President and CEO of Precigen, a Maryland-based commercial-stage biopharmaceutical company, and member of the Precigen Board of Directors. She brings extensive expertise in research and development of immunotherapy-based therapeutics and experience translating novel treatments from pre-clinical stage into the clinic. Previously, she co-founded and served as Chief Scientific Officer of Compass Therapeutics and held leadership roles in Immuno-Oncology and Global Research and Early Development at Merck KGaA/EMD Serono. Dr. Sabzevari received her doctorate degree in cell and molecular immunology and completed her postdoctoral work at the Scripps Research Institute.
Seminars
Wednesday 16th September 2026
Developing the UltraCAR-T® Platform to Expand Patient Access & Drive Scalable Manufacturing in Next-Generation Cell Therapy
9:50 am
Thursday 17th September 2026
Panel Discussion: Accelerating Veinto-Vein Time through Innovative QC Testing Strategies
2:35 pm
- Exploring rapid sterility testing methods, including ATP release assays and NGS-based microbial detection, to reduce traditional 7-day timelines
- Implementing rapid QC testing to accelerate vein-to-vein time without compromising safety and regulatory compliance
- Highlighting emerging technologies demonstrating rapid, reliable testing to support clinical and commercial qc workflows
